A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors

被引：0
|
作者：
Atreya, Chloe E. [1 ]
Ruiz-Saenz, Ana [1 ]
Wang, Changjun [1 ]
Pan, Bo [1 ]
Dreyer, Courtney A. [1 ]
Brunen, Diede [2 ]
Prahallad, Anirudh [2 ]
Spassov, Danislav [1 ]
Steffen, Dana J. [3 ]
Hann, Byron C. [1 ]
VandenBerg, Scott R. [1 ]
Gutkind, Silvio [3 ]
Moasser, Mark M. [1 ]
van't Veer, Laura J. [1 ]
Coppe, Jean-Philippe [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Univ Calif San Diego, San Diego, CA 92103 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-19-B023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B023
引用
收藏
页数：3
相关论文
共 35 条
  • [21] BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis
    Qi Wang
    Wei-guo Hu
    Qi-bin Song
    Jia Wei
    ChineseMedicalSciencesJournal, 2014, 29 (04) : 197 - 203
  • [22] MAP2K1-mutated melanocytic tumors have reproducible histopathologic features and share similarities with melanocytic tumors with BRAF V600E mutations
    Alomari, Ahmed K.
    Harms, Paul W.
    Andea, Aleodor A.
    Warren, Simon J.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2023, 50 (12) : 1083 - 1093
  • [23] Network propagation of the kinase activity signatures of therapy-resistant tumors reveals novel druggable targets in BRAF(V600E)-mutated colorectal cancer.
    Hwang, Yeonjoo
    Bouhaddou, Mehdi
    Moelders, Christina
    Munoz, Denise P.
    Atreya, Chloe E.
    Coppe, Jean-Philippe
    CANCER RESEARCH, 2022, 82 (23)
  • [24] Long-Term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model
    Danysh, Brian P.
    Rieger, Erin Y.
    Sinha, Deepankar K.
    Evers, Caitlin V.
    Cote, Gilbert J.
    Cabanillas, Maria E.
    Hofmann, Marie-Claude
    ONCOTARGET, 2016, 7 (21) : 30907 - 30923
  • [25] Yes-activated protein promotes primary resistance of BRAF V600E mutant metastatic colorectal cancer cells to mitogen-activated protein kinase pathway inhibitors
    Su, Meng
    Zhan, Lei
    Zhang, Yong
    Zhang, Jingdong
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (03) : 953 - 963
  • [26] Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells
    Wu, Chung-Pu
    Sim, Hong-May
    Huang, Yang-Hui
    Liu, Yen-Chen
    Hsiao, Sung-Han
    Cheng, Hsing-Wen
    Li, Yan-Qing
    Ambudkar, Suresh V.
    Hsu, Sheng-Chieh
    BIOCHEMICAL PHARMACOLOGY, 2013, 85 (03) : 325 - 334
  • [27] Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells
    Wu, Chung-Pu
    Sim, Hong-May
    Huang, Yang-Hui
    Liu, Yen-Chen
    Hsiao, Sung-Han
    Cheng, Hsing-Wen
    Li, Yan-Qing
    Ambudkar, Suresh
    Hsu, Sheng-Chieh
    CANCER RESEARCH, 2013, 73 (08)
  • [28] KRAS CODON 61, 146 AND BRAF V600E MUTATIONS PREDICT RESISTANCE TO CETUXIMAB PLUS IRINOTECAN IN KRAS CODON 12 AND 13 WILD-TYPE METASTATIC COLORECTAL CANCER
    Ruzzo, Annamaria
    Loupakis, Fotios
    Canestrari, Emanuele
    Cremolini, Chiara
    Vincenzi, Bruno
    Salvatore, Lisa
    Santini, Daniele
    Masi, Gianluca
    Stasi, Irene
    Rulli, Eliana
    Floriani, Irene
    Bencardino, Katia
    Galluccio, Nadia
    D'Emidio, Silvia
    Catalano, Vincenzo
    Tonini, Giuseppe
    Magnani, Mauro
    Falcone, Alfredo
    Graziano, Francesco
    ANNALS OF ONCOLOGY, 2009, 20
  • [29] Circulating tumor DNA (ctDNA) dynamics of response and resistance in BRAF V600E mutant (mt) metastatic colorectal (mCRC) and other cancers: Data from EVICT (erlotinib and vemurafenib in combination trial)
    Tan, L.
    Tran, B.
    Tie, J.
    Link, E.
    Wong, S. Q.
    Chandrashekar, S.
    Guinto, J.
    Markman, B.
    Ananda, S.
    Tebbutt, N. C.
    Michael, M.
    Solomon, B. J.
    McArthur, G.
    Gibbs, P.
    Dawson, S-J.
    Desai, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1307 - S1307
  • [30] DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with encorafenib and cetuximab in BRAF V600E mutant colorectal cancer models
    Bogdan, Madhumita
    Timson, Mary J.
    Al-Hashimi, Hikmat
    Smith, Bryan D.
    Flynn, Daniel L.
    CANCER RESEARCH, 2023, 83 (07)
1234